The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies: Trends in Cancer
ASCO 2016 - Brystkræft
Development and strategies of CDK4/6 inhibitors | Future Medicinal Chemistry
Medicinrådets protokol for vurdering vedr. alpelisib til ER+HER2- brystkræft med PIK3CA-mutation-vers. 1.0
Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation - ScienceDirect
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer - ScienceDirect
CDK4/6 inhibition in breast cancer: current practice and future directions. - Abstract - Europe PMC
HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles | Bentham Science
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences | SpringerLink
The application and prospect of CDK4/6 inhibitors in malignant solid tumors | Journal of Hematology & Oncology | Full Text
Therapy options after CDK4/6 inhibitors for HR+, HER2- postmenopausal metastatic/recurrent breast cancer in Japan: a role for mammalian target of rapamycin inhibitors? | Future Oncology
Medicinrådets vurdering vedr. alpelisib i komb. med fulvestrant til metastatisk brystkræft-vers 1.0
Medicinrådets lægemiddelrek. og beh.vejl. vedr. CDK46-hæmmere til ER+HER2- lokalt fremskreden eller metastatisk brystkræft
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. - Abstract - Europe PMC
Cancers | Free Full-Text | Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study
A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib - ScienceDirect
Ribociclib
A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status | SpringerLink
Frontiers | CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
Frontiers | CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
The application and prospect of CDK4/6 inhibitors in malignant solid tumors | Journal of Hematology & Oncology | Full Text
